Korro Bio, Inc (KRRO) 8-K, filed Jun 12, 2020

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2020

FREQUENCY THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-39062	47-2324450
(State or Other Jurisdiction<br><br><br>of Incorporation)	(Commission<br><br><br>File Number)	(IRS Employer<br><br><br>Identification No.)

19 Presidential Way, 2^nd^ Floor

Woburn, MA 01801

(Addressof principal executive offices) (Zip Code)

(866) 389-1970

(Registrant’s telephone number, include area code)

N/A

(Former Name orFormer Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2 below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17<br>CFR 240.14a-12)
---	---
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
---	---
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
---	---

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading<br><br><br>Symbol(s)	Name of each exchange<br><br><br>on which registered
Common stock, par value $0.001 per share	FREQ	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.<br><br><br><br> <br>On June 11, 2020, Frequency Therapeutics, Inc. (the<br>“Company”) held its Annual Meeting of Stockholders. A total of 19,695,746 shares of common stock were present in person or represented by proxy at the meeting, representing approximately 63.5 percent of the Company’s outstanding<br>common stock as of the April 13, 2020 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the<br>Securities and Exchange Commission on April 29, 2020.<br> <br><br> <br>Item<br>1 — Election of two Class I directors to serve until the 2023 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.
NOMINEE	Votes FOR		Votes AGAINST		Votes WITHHELD		Broker Non-Votes
---	---	---	---	---	---	---	---	---
Marc A. Cohen		16,184,449		0		1,891,468		1,619,829
David L. Lucchino		16,358,340		0		1,717,577		1,619,829
Item 2 — Ratification of the appointment of RSM US LLP as the Company’s independent registered public<br>accounting firm for the year ending December 31, 2020.
---
Votes FOR	Votes AGAINST		Votes ABSTAINED		Broker Non-Votes
---	---	---	---	---	---	---
19,658,678		12,665		24,403		0

Based on the foregoing votes, Marc A. Cohen and David L. Lucchino were elected as Class I directors and Item 2 was approved.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	FREQUENCY THERAPEUTICS, INC.
Date: June 12, 2020	By:	/s/ Michael D. Bookman
		Name: Michael D. Bookman
		Title: Deputy General Counsel and Secretary

Korro Bio, Inc 8-K, filed Jun 12, 2020

About this 8-K

Items reported